Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Experimental Nephrology
Published in: Clinical and Experimental Nephrology 1/2018

01-02-2018 | Letter to the editor

Is a liver biopsy necessary to diagnose hemodialysis-related portal-systemic encephalopathy (HRPSE)? A proposal of the concise diagnostic criteria for HRPSE

Authors: Tsuyoshi Takashima, Sae Hirata, Makoto Fukuda, Motoaki Miyazono, Yuji Ikeda

Published in: Clinical and Experimental Nephrology | Issue 1/2018

Login to get access

Excerpt

To the Editor …
Literature
1.
Sherlock S, Summerskill WH, White LP, Phear EA. Portal-systemic encephalopathy; neurological complications of liver disease. Lancet. 1954;267(6836):454–7.PubMed
2.
3.
Ubara Y, Hoshino J, Tagami T, Sawa N, Katori H, Takemoto F, et al. Hemodialysis-related portal-systemic encephalopathy. Am J Kidney Dis. 2004;44(3):e38–42.CrossRefPubMed
4.
Oi K, Okado T, Togo H, Iimori S, Yui N, Sohara E, et al. Two cases of hemodialysis-associated chronic portal-systemic shunt encephalopathy (CPSE) with opposite changes in the blood ammonia concentrations during hemodialysis: a case report and literature review. Intern Med. 2015;54(11):1375–80. doi:10.​2169/​internalmedicine​.​54.​3488.CrossRefPubMed
5.
Takashima T, Ohtsuka T, Sato S, Yoshizaki M, Kamachi S, Kishi T, et al. Episodic confusion in a haemodilaysis patient due to haemodialysis-related portal-systemic encephalopathy and a shunt between the left portal vein and left external iliac vein. Nephrology. 2017;22(4):332. doi:10.​1111/​nep.​12786.CrossRefPubMed
Metadata
Title
Is a liver biopsy necessary to diagnose hemodialysis-related portal-systemic encephalopathy (HRPSE)? A proposal of the concise diagnostic criteria for HRPSE
Authors
Tsuyoshi Takashima
Sae Hirata
Makoto Fukuda
Motoaki Miyazono
Yuji Ikeda
Publication date
01-02-2018
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 1/2018
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-017-1410-0

Other articles of this Issue 1/2018

Clinical and Experimental Nephrology 1/2018 Go to the issue

Original article

Serum adipocyte fatty acid-binding protein level is associated with arterial stiffness quantified with cardio-ankle vascular index in kidney transplant patients

Erratum

Erratum to: Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial)

Original article

Night-time blood pressure and pulse wave velocity in dialysis patients

Original article

Comparison of different definitions of acute kidney injury in extremely low birth weight infants

Images in nephrology

Neuroblastoma invading the kidney through the renal hilum

Original article

A randomized, controlled clinical trial to evaluate the immunogenicity of a PreS/S hepatitis B vaccine Sci-B-Vac™, as compared to Engerix B®, among vaccine naïve and vaccine non-responder dialysis patients
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits